期刊名称：CELL CYCLE
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Cell Cycle is a new print and online (indexed by Pubmed/Medline and ISI) multidisciplinary journal. There are no restrictions on topics and formats. We will consider any interesting manuscript in most fields of biology (from yeast to man) and medicine (from cancer to cardiology), including, but not limited to, basic and cancer cell cycles, signal transduction, molecular and cell biology, apoptosis, senescence, cell functions in norm and disease, development and evolution. We emphasize a flexible format of the articles and there is no limit for the number of pages. Papers may be short with one outstanding experiment, or as long as necessary (in the latter case, please refer to the section in the Author Guidelines regarding page charges). The only requirements for submission are novelty, significance and interest for a wide readership.
Cell Cycle is an ideal vehicle for experimental reports in the most competitive areas for the following reasons:
- Rapid response to presubmission inquiries (usually within the hour)
- Submission by e-mail
- Ultra-rapid review
- Special submission
- Papers rejected from other top journals (e.g., Nature, Cell), if the authors choose, may be submitted with previous reviews and decision letters. This allows for the consideration of a paper without sending for additional review.
- Ultra-rapid publication upon acceptance. Papers are published online within one week of acceptance. In the optimal scenario, the paper may be published the day following acceptance.
- Ultra-rapid publication on PubMed/Medline with a link out to a full-length paper in press.
Instructions to Authors
|
MANUSCRIPT SUBMISSION
Authors may choose to submit manuscripts electronically or via regular mail.
Pre-Submission Inquiries
Pre-submission inquiries are encoruaged. These may include either an abstract or a full length manuscript as an email attachment (Microsoft Word). Pre-submission inquiries should be emailed to the Editor, Mikhail V. Blagosklonny.
Special Submission
Cell Cycle will reconsider papers that have been rejected by Cell, Genes and Development, Nature and Science, in the original format of those journals, thus saving the authors effort and time. The authors are encouraged to enclose the reviewers' and/or editorial comments from the above mentioned journals. This will expedite the evaluation of the article. Upon acceptance, the authors should provide the paper in Cell Cycle format.
General Submission
Electronic Submission (Email or FTP)
Initial submission:
One (1) PDF file that includes all text, tables, figures, and references. It is important that we receive a the manuscript as a PDF for not only will it expedite the peer-review process, but it allows for the cross-platform distribution of your paper with a minimum loss of text, symbols, etc. PDFs should be compatible with Acrobat Reader 3.0.
Submission following acceptance of manuscript:
1. One (1) PDF file that contains text, tables, figures, and references. Again, it is important that we recieve the PDF to double-check the formatting of text, especially as regards italicization, greek symbols, super/subscripts, etc. Such formatting is ocassionally lost in MS Word. PDFs should be compatible with Acrobat Reader 3.0.
2. A MS Word document with the full text of the manuscript and any figure legends.
3. A MS Word document with any tables the manuscript may contain.
4. Figures should be in a separate file (or files). Please refer to the section regarding illustrations for the required electronic format.
Please email submission to Kim Mitchell and Mikhail V. Blagosklonny.
If your files are too large to send via email, please contact Kim Mitchell for FTP details.
All submissions must be accompanied by a completed copyright transfer form. Fax to Kim Mitchell at 512.863.0081
Submission Via Regular Mail
If electronic submission in PDF format is not possible, please send one good quality hardcopy (including figures) along with a disk ( CD-ROM or Zip) containing a file with the full text of the manuscript and separate files containing the figures and tables. This file should be in Microsoft Word format.
Send to:
Kimberly Mitchell ?Cell Cycle
Landes Bioscience ?810 S. Church St.
Georgetown, TX 78626 ?USA
Manuscript Evaluation Process
A copyright transfer form must accompany all submissions. If you submit your manuscript electronically, please fax a copy of these to Kim Mitchell at 512.863.0081. |
|
EDITORIAL GUIDELINES
Text should be double-spaced, with page numbers throughout. Papers should be written as concisely as possible in clear, grammatical English and organized in the following fashion.
1. Title page, including titles, authorÕs names (first, MI, last) and affilitations,
2. 5-10 key words (for indexing purposes),
3. acknowledgements,
4. a list of abbreviations and acronyms used throughout the text,
5. an abstract, the primary goal of which is to make the general significance and conceptual advance of the work clearly accessible to a broad readership. References should not be cited in the abstract.
6. a running title of no more than 50 characters in length
7. Text (length and organization depends upon type of paper; see below).
8. References
9. Tables (with descriptive titles and legends)
10. Figure legends |
Types of Papers
Reports
Full Length Reports
Reports include the following sections:
- Abstract: A single paragraph of fewer than 250 words. The primary goal of the abstract should be to make the general significance and conceptual advance of the work clearly accessible to a broad readership. References should not be cited in the abstract.
- Key Words: 5-10, for indexing purposes.
- Introduction
- Materials and Methods
- Results
- Discussion
- References: Please see section below for reference format.
Brief Reports
These are short experimental papers that may present as little as a single experiment or observation. Brief Reports should constitute unusually interesting data combined with a discussoin of what the data might mean, or an explantation of why the data contradicts current paradigms.
Abstract includes a single paragraph of fewer than 150 words. The primary goal of the abstract should be to make the general significance and conceptual advance of the work clearly accesible to a broad readership.
Please include 5-10 key words for indexing purposes.
Reviews
Although reviews should be recognized as scholarly by specialists in the field being covered, they also should be written with a view to informing readers who are not specialized in that particular field, and should therefore be presented using simple prose.
Please include an abstract of 150-200 words and 5-10 key words for indexing purposes.
Perspectives
A focused review or theoretical paper that is primarily addressed to the experts in the field. It may emphasize an opinion of the authors', present a concept, or authors' credo. Abstract includes a single paragraph of fewer than 150 words.
Please include an abstract of 150-200 words and 5-10 key words for indexing purposes.
Extra-Views
For extra-views (auto-commentary), the Editorial Board will solicit authors of the most significant recent and forthcoming papers, published elsewhere, to provide a short summary with additional insights, new interpretations or speculation on the relevant topic. These manuscripts may include data or models which due to space limitations were not included or discussed in the original paper. In other words, the authors may provide biased and uncensored points of views, complementing their article. As with other papers published in Cell Cycle, extra-views will appear on-line, in print and on MedLine/Pubmed. Extra-views will appear simultaneously, or very soon after, publication of the original paper.
Please include an abstract of 150-200 words and 5-10 key words for indexing purposes.
Retro-Views
Retro-views re-visit and re-interpret (by original authors) important articles that directly or indirectly led to significant ideas and discoveries.
Please include an abstract of 150-200 words and 5-10 key words for indexing purposes.
Story of Discovery
This rubric is similar to Retro-Views; personal account of the discovery.
Please include an abstract of 150-200 words and 5-10 key words for indexing purposes.
Views and Commentaries
Either short and focused opinion-articles or commentaries on papers recently published in Cell Cycle and elsewhere. May include figures and up to 30 references.
Please include an abstract of 150-200 words and 5-10 key words for indexing purposes.
Trends in Science
Commentaries on most significant conceptual changes and on groundbreaking phenomena described in recent years, envisioning potential conceptual framework for these phenomena. Commentaries on "best papers of the year". We also invite authors to propose important trends and predict directions in science (with examples of relevant publications).
Please include an abstract of 150-200 words and 5-10 key words for indexing purposes.
Meeting Reports
Authors are encouraged to contact the Editor with proposals for meeting reports. Also, please contact the meeting organizers to verify that reports will be permitted.
Please include an abstract of 150-200 words and 5-10 key words for indexing purposes.
Book Reviews
The Editorial Board will solicit reviews of significant, recently published books.
References
Help get Cell Cycle's reference format listed in Endnotes. Click here for more information.
References for review articles are limited to 150. For research papers, please limit references to 85. References in the text are numbered consecutively as superscripts beginning with number 1. Punctuation always precedes the superscript.
The list of references should be numbered consecutively according to the first time mentioned within the article. Abbreviate journal names according to the style used in Index Medicus or a comparable source and omit punctuation after journal titles. Spell out foreign or less commonly known journal names.
Example:
...according to Jones.1
not …Jones1.
...noted by Smith et al.1
not ...Smith et al (1).
When referring the reader to specific references as part of a sentence, cite as:
Example:
For a review see refs. 20-25.
not ...For a review see 20-25
Journals: [Author’s last name] [Author’s initials], [Other authors?last names followed by their initials]. [Title of article with only first word capitalized]. [Journal’s standard abbreviated name] [Year]; [Volume (number)]:[Inclusive pages].
List all authors. Initials and abbreviations are not followed by periods.
-Unpublished data and personal communications are not listed as references but rather appear in parentheses in the text.
Examples:
1. Darzynkiewicz Z, Sharpless T, Staiano-Coico L, Melamed R. Subcompartments of the G1 phase of cell cycle detected by flow cytometry. Proc Natl Acad Sci USA 1980; 77:6696-9.
2. Fisher MJ, Virmani AK, Wu L, Aplenc R, Harper JC, Powell SM, Rebbeck TR, Sidransky D, Gazdar AF, El-Deiry WS. Nucleotide substitution in the ectodomain of trail recepto dr4 is associated with lung cancer and head and neck cancer. Clin Cancer Res 2001; 7:1688-97.
Books: [Author’s last name] [Author’s initials], [Other authors?last names followed by initials]. [Chapter title]. In: [Editor’s last name] [Editor’s initials], ed(s). [Book Title]. [Number of edition]. [City]:[Publisher], [Year]:[Inclusive pages].
Example:
1.MacLachlan T, El-Deiry WS. Functional interactions between BRCA2 adn the cell cycle. In: Blagosklonny MV, ed. Cell Cycle Checkpoints and Cancer. Austin: Landes Bioscience, 2001:126-34.
PRODUCTION GUIDELINES
How to prepare text files
Please save text and table files as Microsoft Word documents. Save tables in a file separate from text. Figure captions, however, can be at the end of the manuscript as text. There is no need to make a unique file for captions. Tables will be reformatted during production and therefore need only be minimally formatted in your text file.
How to prepare figures, illustrations & photos
Figures should be provided as TIFF files (300 dpi or greater), MS Powerpoint Files or PDF files. Compatible computer graphics programs are Adobe Illustrator, Adobe Photoshop, and Microsoft Powerpoint.
Figures and illustrations may be provided by authors as HIGH-QUALITY hard copy as well, with two copies of each illustration submitted. All artwork submitted as hard copy should be labeled with the authorÕs name, the figure number and the correct orientation of the figure, but be sure that labeling is clear of the image. Do not put the label directly behind the image. Do not write directly on the back of thephotograph or on the label after it has been applied. Indicate any special cropping on a photocopy of the figure.
Send only original artwork, no photo-copies. Photography will be published only if the quality is reproducible.
When illustrations are reproduced from other sources, acknowledge the copyright holder at the end of the figure legend or as a footnote to tables. Do not use superscripted reference numbers in lieu of a full credit line.
There will be a solution if you cannot submit your manuscript and/or figures in the desired format. Please contact Kathryn Sauceda before you send your work, if you have problems or questions.
PAGE CHARGES
Accepted manuscripts will be published with the understanding that the author will pay a charge of $80 USD for pages 5 and greater (there is no charge for the first four pages).
Under exceptional circumstances, when no grant or other source of support exists, the author(s) may apply (at the time of submission) to Dr. Mikhail V. Blagosklonny, Editor-in-Chief, for a waiver of the page charges. All applications must be countersigned by an appropriate institutional official stating that no funds are available for the payment of page charges.
COLOR CHARGES
The cost of printing color images within an article is the responsibility of the author. Charges will be advised by the publisher, Landes Bioscience, at the galley proof stage at a cost of $340 for the first color page and $150 for each additional color page. Alternatively, figures can be posted in color to the version published on-line at no cost and printed in black and white.
PAGE PROOFS
Page proofs should be returned within two working days, preferably by email, fax or overnight mail. Corrections should be marked on the actual proof and provided in a numbered list. Lengthy additions should be avoided, but where necessary should be provided on disk with written instructions.
REPRINTS
Reprints may be ordered at the proof stage. Prices depend upon the quantity ordered and length of article.
Editorial Board
Jiri Bartek
Institute of Cancer Biology
Copenhagen, Denmark
Kapil N. Bhalla
Moffit Cancer Center
Tampa, FL
W. Robert Bishop
Schering-Plough Research Inst.
Kenilworth, NJ
Judith Campisi
Lawrence Berkeley National Lab.
Berkeley, CA
Tony Carr
Sussex University
Brighton, UK
Duncan J. Clarke
University of Minnesota
St. Paul, MN
Carlo M. Croce
Kimmel Cancer Center
Philadelphia, PA
Zbigniew Darzynkiewicz
New York Medical College
Hawthorne, NY
Ronald A. DePinho
Harvard University
Boston, MA
Brian J. Druker
Oregon Health Science University
Portland, OR
Wafik S. El-Deiry
University of Pennsylvania
Philadelphia, PA
David E. Fisher
Harvard University
Boston, MA
Tito Fojo
National Institutes of Health
Bethesda, MD
Judah Folkman
Harvard Medical School
Boston, MA
Stephen H. Friend
Merck
West Point, PA
Paraskevi Giannakakou
Emory University
Atlanta, GA
Steven Grant
Medical College of Virginia
Richmond, VA
Andrei V. Gudkov
The Cleveland Clinic Foundation
Cleveland, Ohio
William C. Hahn
Harvard Medical School
Boston, MA
Ygal Haupt
The Hebrew University
Jerusalem, Israel
Tony Hunter
The Salk Institute
La Jolla, CAl
Robert S. Kerbel
Health Sciences Centre
Toronto, Ontario, Canada
Eugene V. Koonin
National Institutes of Health
Bethesda, MD
David P. Lane
University of Dundee
Dundee, UK
Christoph Lengauer
Johns Hopkins University
Baltimore, MD
Arnold Levine
Institute for Advanced Study
Princeton, NJ
Chiang J. Li
ArQule Biomedical Institute
Norwood, MA
Michael P. Lisanti
Albert Einstein College of Medicine
Bronx, NY
James A. McCubrey
East Carolina University
Greenville, NC
Giovanni Melillo
National Cancer Institute
Frederick, MD
Gerry Melino
University of Rome
Rome, Italy
Donald Metcalf
The Royal Melborne Hospital
Melborne, Austalia
Yusuke Nakamura
University of Tokyo
Tokyo, Japan
Paul Nurse
Imperial Cancer Research Fund
London, UK
Moshe Oren
The Weizmann Inst. of Science
Rehovot, Israel
Michele Pagano
New York University
New York, NY
Arthur B. Pardee
Harvard University
Boston, MA
Helen Piwnica-Worms
HHMI and Washington University
St.Louis, MO
Carol Prives
Columbia University
New York, NY
Martin Raff
University College London
London, UK
E. Premkumar Reddy
Fels Institute, Temple University
Philadelphia, PA
John C. Reed
The Burnham Institute
La Jolla, CA
Steven I. Reed
The Scripps Institute
La Jolla, CA
James M. Roberts
Howard Hughes Medical Inst.
Seattle, WA
Igor B. Roninson
Ordway Research Institute
Albany, NY
Martine Roussel
St. Jude's Children's Hospital
Memphis, TN
Leo Sachs
The Weizmann Inst. of Science
Rehovot, Israel
Edward A. Sausville
National Cancer Institute
Rockville, MD
Charles L. Sawyers
UCLA
Los Angeles, CA
Charles J. Sherr
St. Jude's Children's Hosptial
Memphis, TN
Piotr Sicinski
Harvard Medical School
Boston, MA
George F. Vande-Woude
Van Andel Research Inst.
Grand Rapids, MI
Bert Vogelstein
Johns Hopkins University
Baltimore, MD
Peter K. Vogt
The Scripps Research Institute
La Jolla, CA
Karen Vousden
Beatson Inst, for Cancer Res.
Glasgow, UK
Paul Workman
Cancer Research UK
Sutton, UK
Michael B. Yaffe
Massacusetts Institute of Technology
Cambridge, MA
Yi-Xin Zeng
Sun Yat-sen Univ
Guang Zhou, China
Boris Zhivotovsky
Karolinska Institutet
Stockholm, Sweden
Harald zur Hausen
DeutschesKrebsforschungszentrum
Heidelberg, Germany
|
